|
1
|
Borner K, Chen CM and Boyack KW:
Visualizing knowledge domains. Annu Rev Inf Sci Technol.
37:179–255. 2003. View Article : Google Scholar
|
|
2
|
Chen Y and Liu ZY: The rise of mapping
knowledge domain. Studies in Science of Science. 23:149–154.
2005.
|
|
3
|
Jankovic MP, Kaufmann M and Kindler CH:
Active research fields in anesthesia: a document co-citation
analysis of the anesthetic literature. Anesth Analg. 5:1524–1533.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jarneving B: A comparison of two
bibliometric methods for mapping of the research front.
Scientometrics. 2:245–263. 2005. View Article : Google Scholar
|
|
5
|
Lee MR and Chen TT: Revealing research
themes and trends in knowledge management: from 1995 to 2010.
Knowledge-Based System. 28:47–58. 2012. View Article : Google Scholar
|
|
6
|
Zhao R and Wang J: Visualizing the
research on pervasive and ubiquitous computing. Scientometrics.
86:593–612. 2011. View Article : Google Scholar
|
|
7
|
Chen CM, McCain K, White H and Lin X:
Mapping Scientometrics (1981–2001). In: Proc 65th Asist Annual
Meeting; 39. pp. 25–34. 2002
|
|
8
|
An XY and Wu QQ: Co-word analysis of the
trends in stem cell field based on subject heading weighting.
Scientometrics. 88:133–144. 2011. View Article : Google Scholar
|
|
9
|
Chen CM: CiteSpace II: detecting and
visualizing emerging trends and transient patterns in scientific
literature. J Am Soc Inf Sci Technol. 57:359–377. 2006. View Article : Google Scholar
|
|
10
|
Chen C, Ibekwe-San Juan F and Hou J: The
structure and dynamics of cocitation clusters: a
multiple-perspective cocitation analysis. J Am Soc Inf Sci Technol.
61:1386–1409. 2010. View Article : Google Scholar
|
|
11
|
Chen CM: Searching for intellectual
turning points: progressive knowledge domain visualization. Proc
Natl Acad Sci USA. 101:5303–5310. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen CM, Cribbin T, Macredie R and Morar
S: Visualizing and tracking the growth of competing paradigms: two
case studies. J Am Soc Inf Sci Technol. 53:678–689. 2002.
View Article : Google Scholar
|
|
13
|
Chen C, Hu Z, Liu S and Tseng H: Emerging
trends in regenerative medicine: a scientometric analysis in
CiteSpace. Expert Opin Biol Ther. 12:593–608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Small H: Co-citation in the scientific
literature: a new measure of the relationship between two
documents. J Am Soc Info Sci. 24:265–269. 1973. View Article : Google Scholar
|
|
15
|
Liu Z, Chen Y and Chen H: Mapping
Knowledge Domains Methods and Application. 1st edition. People
Publishing House; Peking: pp. 34–81. 2008
|
|
16
|
Liu J: An introduction to Social Network
Analysis. 1st edition. Social Science Academic Press; (China),
Beijing: pp. 4–25. 2004
|
|
17
|
Katz JS and Martin BR: What is research
collaboration? Res Policy. 26:1–18. 1997. View Article : Google Scholar
|
|
18
|
Gossart C and Ozman M: Co-authorship
networks in social sciences: the case of Turkey. Scientometrics.
78:323–345. 2009. View Article : Google Scholar
|
|
19
|
Lu HY and Feng YQ: A measure of authors’
centrality in co-authorship networks based on the distribution of
collaborative relationships. Scientometrics. 81:499–511. 2009.
|
|
20
|
Yu Q, Shao H and Duan Z: Research groups
of oncology co-authorship network in China. Scientometrics.
89:553–567. 2011. View Article : Google Scholar
|
|
21
|
Morel CM, Serruya SJ, Penna GO and
Guimarães R: Co-authorship network analysis: a powerful tool for
strategic planning of research, development and capacity building
programs on neglected diseases. PLoS Negl Trop Dis. 3:82009.
View Article : Google Scholar
|
|
22
|
Liu B, Nicolaides NC, Markowitz S, Willson
JKV, Parsons RE, Jen J, Papadopolous N, Peltomäki P, de la Chapelle
A, Hamilton SR, Kinzler KW and Vogelstein B: Mismatch repair gene
defects in sporadic colorectal cancers with microsatellite
instability. Nat Genet. 9:48–55. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Issa JP, Baylin SB and Herman JG: DNA
methylation changes in hematologic malignancies: biologic and
clinical implications. Leukemia. 11:S7–S11. 1997.PubMed/NCBI
|
|
24
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
25
|
Sun C and Wang H: The role of SNAIL gene
in gynecologic cacinoma metastasis mechanism. J Int Obstet Gynecol.
4:260–263. 2010.
|
|
26
|
Tetsu O and McCormick F: Beta-catenin
regulates expression of cyclin D1 in colon carcinoma cells. Nature.
398:422–426. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sionov RV and Haupt Y: The cellular
response to p53: the decision between life and death. Oncogene.
45:6145–6157. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tyner SD, Venkatachalam S, Choi J, Jones
S, Ghebranious N, Igelmann H, Lu XB, Soron G, Cooper B, Brayton C,
Park SH, Thompson T, et al: p53 mutant mice that display early
ageing-associated phenotypes. Nature. 415:45–53. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bond GL, Hu WW, Bond EE, Robins H, Lutzker
SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K,
Yip L, Hwang SJ, Strong LC, Lozano G and Levine AJ: A single
nucleotide polymorphism in the MDM2 promoter attenuates the p53
tumor suppressor pathway and accelerates tumor formation in humans.
Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bodnar AG, Ouellette M, Frolkis M, Holt
SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S and
Wright WE: Extension of life-span by introduction of telomerase
into normal human cells. Science. 279:349–352. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, Ferrara N, Fyfe G, et al: Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer. N
Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo QS and Liu YX: Lung cancer target to
treatment medicine progress. World Clin Drugs. 5:282–285. 2005.
|
|
33
|
Paez JG, Janne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon T,
Naoki K, Sasaki H, et al: EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science.
304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Folkman J: Tumor angiogenesis: therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shi W and Li JS: Clinical significance of
the expression of ADAM9 in colon carcer. J Southeast University
(Medical Science Edition). 4:274–278. 2009.
|
|
37
|
Kerr JF, Wyllie AH and Currie AR:
Apoptosis-basic biological phenomenon with wide-ranging
implications in tissue kinetics. Br J Cancer. 26:239–257. 1972.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu LJ, Peng JX, Hong HZ, Ye W and Qiao
YY: Mitochondrial changes and role in apoptosis. Chin J Cell Biol.
27:117–120. 2005.
|
|
39
|
Green DR and Kroemer G: The
pathophysiology of mitochondrial cell death. Science. 305:626–629.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Deng C and Shao ZW: Apoptosis of
osteosarcoma cells induced by a combination of TRAIL, adriamycin
and IFN-γ. Cancer Res Prev Treat. 1:1–4. 2010.PubMed/NCBI
|
|
41
|
Walczak H, Miller RE, Ariail K, Gliniak B,
Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C,
Smolak P, et al: Tumoricidal activity of tumor necrosis factor
related apoptosis-inducing ligand in vivo. Nat Med. 5:157–163.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ashkenazi A, Pai RC, Fong S, Leung S,
Lawrence DA, Masters SA, Blackie C, Chang L, McMurtrey AE, Hebert
A, DeForge L, Koumenis IL, et al: Safety and antitumor activity of
recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cao ZA, Daniel D and Hanahan D: Sub-lethal
radiation enhances anti-tumor immunotherapy in a transgenic mouse
model of pancreatic cancer. BMC Cancer. 2:112002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rosenberg SA, Yang JC, Schwartzentruber
DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME,
Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, et al:
Immunologic and therapeutic evaluation of a synthetic peptide
vaccine for the treatment of patients with metastatic melanoma. Nat
Med. 4:321–327. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guo Y, Wu M, Chen H, Wang X, Liu G, Li G,
Ma J and Sy MS: Effective tumor vaccine generated by fusion of
hepatoma cells with activated B cells. Science. 263:518–520. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
He TC, Chan TA, Vogelstein B and Kinzler
KW: PPAR delta is an APC-regulated target of non-steroidal
anti-inflammatory drugs. Cell. 99:335–345. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Collado M, Blasco MA and Serrano M:
Cellular senescence in cancer and aging. Cell. 130:223–233. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, et al: New guidelines to
evaluate the response to treatment in solid tumors. J Natl Cancer
Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, et al: EGF receptor gene mutations are common
in lung cancers from ‘never smokers’ and are associated with
sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad
Sci USA. 101:13306–13311. 2004.
|
|
50
|
Blann AD, Lip GY, Islim IF and Beevers DG:
Evidence of platelet activation in hypertension. J Hum Hypertens.
11:607–609. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chou JJ, Li HL, Salvesen GS, Yuan JY and
Wagner G: Solution structure of BID, an intracellular amplifier of
apoptotic signaling. Cell. 96:615–624. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 144:646–674. 2000. View Article : Google Scholar
|
|
53
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, et al: Mutations of the BRAF gene in human
cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jemal A, Siegel R, Ward E, Hao YP, Xu JQ,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
55
|
Chan TA, Hermeking H, Lengauer C, Kinzler
KW and Vogelstein B: 14-3-3 Sigma is required to prevent mitotic
catastrophe after DNA damage. Nature. 401:616–620. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chenevix-Trench G, Spurdle AB, Gatei M,
Kelly H, Sambrook J, et al: Dominant negative ATM mutations in
breast cancer families. J Natl Cancer Inst. 94:205–215. 2002.
View Article : Google Scholar : PubMed/NCBI
|
